GARANGER, Elisabeth; MIGNET, Nathalie; PICHON, Chantal; ROLS, Marie-Pierre; SANCEY, Lucie

doi:10.1016/j.ijpharm.2023.122928

Laboratoire de Chimie des Polymères Organiques [LCPO]
Team 3 LCPO : Polymer Self-Assembly & Life Sciences

MIGNET, Nathalie
Unité de Technologies Chimiques et Biologiques pour la Santé [UTCBS - UM 4 (UMR 8258 / U1267)]

PICHON, Chantal
Université d'Orléans [UO]

Langue

Article de revue

Ce document a été publié dans

International Journal of Pharmaceutics. 2023-05-10, vol. 638, p. 122928

Résumé en anglais

The field of nanomedicine has reached a milestone since the approval of Patisiran, the first ever-approved siRNA drug designed to treat transthyretin (TTR) amyloidosis. The great success of Corminaty and Spikevax messenger RNA (mRNA)-based vaccines against COVID-19 has really brought to light how potent nanomedicine could be. Today, stakeholders are getting more confident in the benefits of nanomedicine for diagnosis, treatment, vaccination, and research related to different types of diseases. For the years to come, it is becoming clear that we need a multidisciplinary approach to achieve a rational design of nanomedicine. Impelling the meeting and discussions of academic and private actors from different disciplines is one of the goals of the French Society for Nanomedicine (SFNano).< Réduire

Mots clés en anglais

Nanomedicine

Drug Delivery Systems

mRNA-based vaccines

siRNA drugs

URI

https://oskar-bordeaux.fr/handle/20.500.12278/182350

DOI

http://dx.doi.org/10.1016/j.ijpharm.2023.122928

Unités de recherche

Laboratoire de Chimie des Polymères Organiques (LCPO) - UMR 5629

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

A special issue dedicated to the 2021 meeting of the French Society for Nanomedicine.

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche